# Sympathoinhibition as a Preferred Second Line Treatment of Obesity Related Hypertension

> **NCT04474899** · PHASE4 · UNKNOWN · sponsor: **Royal Perth Hospital** · enrollment: 120 (estimated)

## Conditions studied

- Obesity
- Hypertension

## Interventions

- **DRUG:** Moxonidine 0.4 MG
- **DRUG:** Amlodipine 5mg

## Key facts

- **NCT ID:** NCT04474899
- **Lead sponsor:** Royal Perth Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-06-24
- **Primary completion:** 2024-02-24
- **Final completion:** 2024-06-24
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2022-09-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04474899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04474899, "Sympathoinhibition as a Preferred Second Line Treatment of Obesity Related Hypertension". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04474899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*